Will post-transplantation cell therapies for pediatric patients become standard of care?
Will post-transplantation cell therapies for pediatric patients become standard of care?
复制标题
儿科患者的移植后细胞疗法会成为标准护理吗？
DOI：
10.1016/j.bbmt.2014.07.018
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
WesthafenInt
中科院分区：
文献类型：
--
作者：
Lankester,ArjanC;Locatelli,Franco;Bader,Peter;Rettinger,Eva;Egeler,Maarten;Katewa,Satyendra;Pulsipher,MichaelA;Nierkens,Stefan;Schultz,Kirk;Handgretinger,Rupert;Grupp,StephanA;Boelens,JaapJan;Bollard,CatherineM;WesthafenInt
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I.
